MedTrace Logo

ImmuniCell® in Patients With Advanced Cancers

NCT02459067 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-03-10

No results posted yet for this study

Summary

To determine the safety, tolerability, maximum tolerated dose (MTD) and efficacy of ImmuniCell® in patients with melanoma, renal cell cancer (RCC) or non-small cell lung cancer (NSCLC). The study is an adaptive design that has 3 stages: Stage 1 - dose escalation, Stage 2 - efficacy, and Stage 3 - confirm efficacy in one of the tumor types.

Conditions

Interventions

BIOLOGICAL

ImmuniCell®

Autologous γδ T Lymphocytes

Sponsors & Collaborators

  • TC Biopharm

    lead INDUSTRY

Principal Investigators

  • Jeff Evans, Prof. · Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-11-27
Completion
2018-11-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02459067 on ClinicalTrials.gov